3D print of Pembrolizumab (KEYTRUDA) bound to PD-1. Model available in multiple materials and sizes. “Pembrolizumab (formerly MK-3475and lambrolizumab, trade name Keytruda) is a humanized antibodyused in cancer immunotherapy. It destroys a protective mechanism on cancer cells, and allows the immune system to destroy those cancer cells. It targets the programmed cell death 1(PD-1) receptor. The drug was initially used in treating metastatic melanoma.”
Pembrolizumab is a compact antibody used in the treatment of various cancers, most notably indicated for use when EGFR inhibitors fail to reach treatment outcomes. Scientists identified the programmed cell death 1 receptor, PD-1, a protective mechanism on the surface of cancer cells. Pembrolizumab binds to this receptor allowing for the immune system cells to successfully recognize and destroy cancer cells.